Patent Application
20200093843
The present invention relates to the field of neurodegenerative diseases, and the prevention and/or treatment of TBC1D24-associated disorders, such as DOORS syndrome, (intractable) epilepsy, and nonsyndromic deafness. In particular, the present invention relates to phosphoinositide phosphatase inhibitors and screening methods for producing such inhibitors, more particularly, Synaptojanin-1 5′ phosphatase inhibitors, to increase phosphatidylinositol 4,5-bisphosphate (PI(4,5)P2) levels in neuronal cells.
TBC1D24 encodes a protein with an N-terminal TBC (Tre2/Bub2/Cdc16) domain linked to a TLDc (TBC/LysM) domain. This combination of a TBC domain and a TLDc domain is unique amongst human proteins15, but orthologues with the same domain organization are found in many other species including Drosophila melanogaster where the gene is called skywalker (sky). Mutations in TBC1D24 cause early onset epilepsy accompanied with variable degrees of intellectual disability1-6, hearing loss7-10 and cortical myoclonus and cerebellar ataxia11. In addition, DOORS syndrome (deafness, onychodystrophy, osteodystrophy, mental retardation and seizures) is attributed to mutations in TBC1D2412,13. Most mutations are recessive loss of function mutations14, but how these mutations affect protein activity and neuronal function is unknown. Fruit flies with such pathogenic mutations also show severe neurological defects, including impaired synaptic vesicle trafficking and seizures.
Although TBC domains typically interact with small GTPases that regulate vesicle trafficking16, TBC1D24 and Skywalker contain an atypical TBC domain that lacks the arginine and glutamine residues15 required for stimulating GTPase activity, suggesting that they might use an alternative mechanism to catalyze GTP hydrolysis20. Currently, the knowledge is lacking to determine how pathogenic mutations affect TBC1D24 function.
Phosphatidylinositol (PI) signaling is tightly regulated by a number of enzymes, such as kinases, phosphatases, and phospholipases. In the central nervous system, the levels of PIs in nerve terminals are regulated by specific synaptic phosphatidylinositol phosphate phosphatases, such as synaptojanin 1 (SYNJ1), but also kinases. Within the field of intractable epilepsy, mutations in the catalytic domain of phosphoinositide 3-kinases (PIK3ca mutations) were shown to cause pathological effects, meaning that PI3K inhibitors envisage a new avenue for anti-epileptic therapy59. Such kinase inhibitors potentially also impact the PI(4,5)P2 levels, and therefore a Pl3K inhibitor could further increase the possibilities for treatment of refractory epilepsy.
Synaptojanin-1 encodes a polyphosphatidylinositol phosphatase containing two consecutive phosphatase domains, and plays a role in neuronal synaptic vesicle dynamics. The one phosphatase domain Sacl was previously functionally linked to parkinsonism, and the reduction of the dual phosphatase activity of both domains was shown to underlie severe neonatal refractory epilepsy60.
It would be advantageous to unravel the TBC1D24 structure to search for treatments that rescue the defects caused by the pathological TBC1D24 mutations, as this could lead to therapeutic solutions for many TBC1D24-associated disorders such as intractable epilepsy, DOORS syndrome and nonsyndromic deafness.
The invention relates to the unravelling of the crystal structure of the TBC domain of Skywalker, which revealed an unusual positively charged pocket that is highly conserved among TBC1D24 orthologues but is absent in other known TBC domains. The most prevalent and severe forms of TBC1D24-induced neurological disease are also caused by mutations that map to this pocket. Surprisingly, this pocket allowed the TBC domain to bind directly to membranes containing phosphoinositides phosphorylated in the 4 and 5 position (e.g. PI(4,5)P2, PI(3,4,5)P3). In presynaptic terminals the pocket mediates binding to the membrane, which is required for normal Skywalker function and restriction of Skywalker mobility. Indeed, pathogenic DOORS syndrome mutations or mutations that neutralize or revert positive charge in the phosphoinositide-binding pocket of Skywalker reduce phosphoinositide binding and cause presynaptic vesicle trafficking defects. In adult fruit flies they elicit seizures and further neurological defects.
Interestingly, genetically increasing phosphatidylinositol 4,5-bisphosphate (PI(4,5)P2), by mutating one copy of the synaptic phosphoinositide phosphatase Synaptojanin25,26, strongly suppressed all the cellular and neurological defects in adult Skywalker cationic-pocket-mutant flies. Hence, identification of compounds which increase PI(4,5)P2 and/or PI(3,4,5)P3 levels, especially in neurons, allows for therapeutic solutions for many TBC1D24-associated disorders such as intractable epilepsy, DOORS syndrome and nonsyndromic deafness. Furthermore, besides acting on the PI(4,5)P2 and/or PI(3,4,5)P3 levels via manipulation of its phosphorylation and dephosphorylation or phosphatase events, one could also affect the hydrolysis in the brain, which occurs in response to stimulation of a large number of receptors via two major signaling pathways thereby providing an alternative targeting opportunity, more specifically: a) the activation of G-protein linked neurotransmitter receptors (e.g. glutamate and acetylcholine), mediated by phospholipase C β (PLCβ), and b) the activation of tyrosine kinase linked receptors for growth factors and neurotrophins (e.g. NGF, BDNF), mediated by PLCγ.
The invention further relates to the identification of phosphoinositide phosphatase inhibitors with the capability to increase PI(4,5)P2 and/or PI(3,4,5)P3 levels as therapeutic candidates for treatment of TBC1D24-associated disorders.
In a first aspect, the invention relates to phosphoinositide phosphatase inhibitors leading to increased PI(4,5)P2 levels in a cell, for use in treatment of TBC1D24-associated disorders. In one embodiment, the TBC1D24-associated disorders, comprise severe forms of epilepsy (early onset epilepsy, familial infantile myoclonic epilepsy (FIME), focal epilepsy, dysarthria, myoclonic epilepsy with dystonia, familial malignant migrating partial seizures of infancy, De Flippo malignant migrating partial seizures of infancy), variable degrees of intellectual disability, hearing loss (nonsyndromic deafness, autosomal-dominant nonsyndromic hearing loss, and dominant nonsyndromic hearing impairment), cortical myoclonus and cerebellar ataxia, and DOORS syndrome (deafness, onychodystrophy, osteodystrophy, mental retardation and seizures).
In a particular aspect, said phosphoinositide phosphatase is Synaptojanin-1, and said inhibitor for use in treatment of TBC1D24-associated disorders, is a Synaptojanin-1 phosphatase inhibitor. In another particular embodiment, said inhibitors or compounds for use in treatment of TBC1D24-associated disorders are Synaptojanin-1 5′ phosphatase domain phosphatase inhibitors. In another embodiment, said phosphoinositide phosphatase inhibitors increase PI(4,5)P2 levels in neuronal cells.
One aspect relates to the invention wherein said phosphoinositide (P1) phosphatase inhibitors, for use in treatment of TBC1D24-associated disorders, are selected from a list of inhibitors consisting of bpV(pic), perifosine, edelfosine, miltefosine, erufosine, or YU144118, or a derivative thereof.
In a specific aspect of the invention, the PI phosphatase inhibitor for use in treatment of TBC1D24-associated disorders is an alkyl phospholipid. A more particular embodiment relates to an alkyl phospholipid, for use in treatment of TBC1D24-associated disorders, wherein said alkyl phospholipid is miltefosine, or a derivative thereof. Alternatively, embodiments are provided wherein said alkyl phospholipid is perifosine, edelfosine, erufosine, or a derivative thereof. Alternative embodiments relate to the phosphoinositide phosphatase inhibitor, for use in treatment of TBC1D24-associated disorders, wherein said inhibitor is YU144118, or a derivative thereof.
In another aspect, the invention relates to a method for producing a phosphoinositide phosphatase inhibitor, characterized in that said inhibitor is a 5′ phosphatase domain-specific Synaptojanin-1 inhibitor, wherein said method comprises: a) an in vitro system comprising, PI(4,5)P2 or PI(3,4,5)P3 substrates, or derivatives thereof, and the Synaptojanin-1 5′ phosphatase domain protein as depicted in SEQ ID NO:1 or a homologue with at least 95% amino acid identity thereof; b) administering a test compound to said in vitro system; c) monitoring phosphatase activity in said in vitro test system, wherein, a reduction in said phosphatase activity as compared to phosphatase activity measured under the same test conditions in the same system without the test compound identifies said test compound as a 5′ phosphatase domain-specific Synaptojanin-1 inhibitor.
The drawings described are only schematic and are non-limiting. In the drawings, the size of some of the elements may be exaggerated and not drawn on scale for illustrative purposes.
(a) Cartoon representation of the structure of Sky1-353 in three different orientations related by a 90° rotation around a vertical axis. The left and right panels show a view on the presumed GTPase binding surface and the surface containing the cationic pocket, respectively. In the middle panel the helices are numbered in accordance with the numbering used in Gyp119. Helices of the N- and C-terminal lobe of the TBC domain are indicated in dark and light green respectively. A sulfate ion that is bound to the cationic pocket is shown as sticks, together with the interacting residues K75, R79 and R281.
(b) Superposition of Sky1-353 onto the Gyp1-Rab33-GDP.AIF3 complex. Sky1-353 is colored as in (a), the TBC domain of Gyp1 is colored light grey and Rab33 dark grey. GDP.AIF3 bound to Rab33 is shown as sticks. The right panel shows a close-up of the boxed region, Rab33 is omitted for clarity. Helix α5 of Gyp1 is replaced by a long loop region in Sky. The catalytic arginine and glutamine fingers of Gyp1 (R343 and Q378) correspond to a histidine and proline in the Sky sequence (H140 and P172).
(c) Surface representation of Sky1-353 shown in the same orientation as in (a) with conservation scores of residues mapped on the surface. The right panel shows a region of high conservation surrounding the bound sulfate ion.
(d) Electrostatic surface representation of Sky1-353 shown in the same orientation as in (a). The residues constituting the cationic pocket surrounding the bound sulfate ion are indicated.
(a) Domain organization of TBC1D24/Sky and the position of the mutations implicated in various epilepsy syndromes (in yellow), DOORS syndrome (in red) and non-syndromic deafness (in green). Nonsense mutations are indicated by *. The corresponding residue numbers in Sky are indicated in grey. The three arginine mutants present in the cationic phosphoinositide-binding pocket are highlighted. The indicated TBC and TLDc domains correspond to the core domain prediction by Pfam. The dotted lines indicate the boundaries of the peptide visible in our Sky1-353 crystal structure.
(b) Localization of residues corresponding to pathological mutations on the Sky1-353 crystal structure. The residues are color-coded according to the associated disease phenotype as in (a). The three arginine residues present in the cationic phosphoinositide-binding pocket are highlighted.
(a) Western blots of liposome flotation assays using wild type Sky1-353 (WT) or PI(4,5)P2-GRIP (a positive control) and Folch lipid liposomes. The input and 6 fractions (after centrifugation) from the top (1) to the bottom (6) are loaded on a SDS-PAGE gel and revealed by Western Blot. The liposomes and associated proteins are present in the top fractions. (N=2 independent experiments).
(b) Western blots of liposome flotation assays using wild type Sky1-353 and liposomes (PC:PS) enriched with 2% of the indicated phosphoinositide. (N=2 independent experiments).
(c) Western blots of liposome flotation assays using wild type or mutant (R79C, R281C, R335P, 3Glu) Sky1-353 and liposomes enriched with 2% (left panel) or 0.5% (right panel) of PI(4,5)P2. (N=2 independent experiments).
(d) Titration curves for binding of IP3 to wild type and mutant Sky1-353 (mean±s.d.). Melting temperatures (Tm) at different ligand concentrations were obtained via thermal shift assays. Plotting the Tm values versus ligand concentration yields binding curves that were fitted on a quadratic equation to obtain KD values. Curves for IP3 binding to wild type Sky1-353 and to the disease-associated mutations R79C, R281C and R335P are shown. The curve for MgSO4 binding to wild type Sky1-353 is shown as a reference. N=3. Right, the calculated KD values.
(e) Crystal structure of Sky1-353 bound to IP3, the head group of PI(4,5)P2. Electrostatic surface representation of Sky1-353 in complex with IP3 (red, negative; blue, positive). Residues that interact with IP3 are indicated. The box represents a close-up of the IP3 binding site. IP3 is represented in dark grey sticks with the 2Fo-Fc electron density map (at 1.3σ) shown as a blue mesh. The interacting residues are shown as sticks with residues that are mutated in DOORS syndrome and nonsyndromic deafness colored red and green, respectively.
(f) Indicative docking model for binding of Sky1-353 to a PI(4,5)P2-containing biological membrane. A POPC (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine) bilayer containing a molecule of PI(4,5)P2 was generated and the Sky1-353-IP3 crystal structure was docked on this membrane by superimposing the protein-bound IP3 group on the membrane-embedded PI(4,5)P2. The presumed GTPase-interaction surface of Sky1-353 is indicated.
(a) Images of neuromuscular junction synaptic boutons during a time course experiment where wild type and mutant GFP-Sky (SkyWT, SkyR79C, SkyR281C and Sky3Glu) in the indicated boutons was bleached (arrow, t=1) and where the recovery of fluorescence was then followed for the next minute (t=2-60 s) (FRAP). Wild type and mutant GFP-Sky are all expressed using nSybGal4 in sky½ mutants (yw eyFLP; FRT40A sky1:FRT40A sky2).
(b) Recovery of fluorescence levels in the bleached bouton area starting at the time point following bleaching and normalized to maximum recovery levels. The solid line indicates a single exponential fit of the recovery kinetics and the horizontal dotted line indicates 63.2% recovery of fluorescence. The grey dotted line is a single exponential fit of the fluorescence recovery following the bleaching of Synaptotagmin-GFP (data points are not shown separately), a synaptic vesicle membrane associated protein that we used as a control for a 100% membrane associated protein. The average time constants τ of fluorescence recovery are shown on the right. N=8. Scale bar: 2 μm. Error bars: SEM. ANOVA, Dunnett: p=0.014 (*).
(a, b) Quantification of the number of FM 1-43 accumulations per boutonic area and images of FM 1-43 labeling (arrows indicate FM 1-43 accumulations) at third instar larval synaptic boutons in control animals (yw eyFLP; FRT40A) and in sky½ mutants (yw eyFLP; FRT40A sky1:FRT40Asky2) as well as in sky½ animals expressing wild type or mutant GFP-Sky (as indicated) using nSybGal4. N=10, 5 animals with 2 NMJs per animal. Scale bar: 2 μm. Error bars: SEM. ANOVA, Dunnett: p<0.0001 (****); ns, not significant, p<0.05 (*), p<0.001 (***), p<0.0001(****). t test (SkyR79C vs SkyR281C): ns, not significant
(c) Transmission electron micrographs of larval synaptic boutons of the following genotypes: sky½ animals (yw eyFLP; FRT40A sky1:FRT40A sky2) expressing wild type Sky (SkyWT) using nSybGal4 (nsyb>); control animals (yw eyFLP; FRT40A); sky½ mutants expressing mutant Sky (SkyR79C or Sky3Glu) using nSybGal4 and sky½ mutants. The insets indicate the synaptic vesicles and larger endosomal/cisternal-like structures.
(d) Quantification of the number of large-diameter vesicles/endosomes (>80 nm) per boutonic area. Scale bar: 1 μm as indicated for SkyWT, and 0.5 μm for sky½. N=8 (control, sky½ and Sky3Glu), N=13 (SkyWT) and N=15 (SkyR79C) bouton profiles from >5 animals. Error bars: SEM. ANOVA, Dunnett: p<0.0001 (****); p<0.05 (*), p<0.001 (***), p<0.0001 (****).
(a, b) Photograph of adult sky½ Drosophila males (yw eyFLP/Y; FRT40A sky1:FRT40A sky2) expressing GFP-SkyWT, GFP-SkyR79C or GFP-Sky3Glu using nSybGal4, following 10 seconds of vortex stimulation. The insets show the seizuring flies upon expressing GFP-SkyR79C or GFPSky3Glu but not GFP-SkyWT and these data are also quantified in (b) as the number of flies that fail to stand within a 5 second period. N=5; Error bars: SEM; ANOVA, Dunnett: p<0.0001(****).
(c) Quantification of flight response of flies with genotypes indicated in (a). sky½ flies expressing GFP-SkyR79C or GFP-Sky3Glu fly significantly worse than those expressing GFPSkyWT (nSybGal4). N=8 (5 flies each time). Error bars: SEM; ANOVA, Dunnett: p<0.0001(****).
(d, e) Quantification of the number of flies (genotypes in (a)) standing when incubated for 3 min at the indicated temperatures (d) or incubated at 36° C. for the indicated time (e). (d) N=40 (SkyWT, Sky3Glu); N=20 (SkyR79C).
(e) N=50 (SkyWT, SkyR79C); N=20 (Sky3Glu). Error bars: SEM.
(f) Quantification (top) of total active time (the number of minutes during which a fly crosses the IR beam at least once) and representation of activity over a 72 h period (bottom) of flies with genotypes indicated in (a). Each horizontal line represents the activity of a single fly during a 24 h period (12 h light and 12 h dark) and each vertical line represents an active minute when the fly crossed the IR beam (at least) once. Error bars: SEM; N=30 (SkyWT, SkyR79C); N=15 (Sky3Glu); ANOVA, Dunnett: p<0.0001; p<0.01 (**), p<0.0001 (****).
(a, b) Recovery of fluorescence levels of wild type and mutant GFP-Sky in a bleached bouton area starting at the time point following bleaching and normalized to maximum recovery levels (a) in the following genotypes: flies expressing GFP-SkyWT using nSybGal4 (SkyWT); flies expressing GFP-SkyR79C using nSybGal4 (SkyR79C) and heterozygous synaptojanin mutants (yweyFLP/yw; FRT42D synj1/+) expressing GFP-SkyR79C using nSybGal4 (synj+/−; SkyR79C). The solid line indicates a single exponential fit of the recovery kinetics and the horizontal dotted line indicates 63.2% recovery of fluorescence. The average time constants τ of fluorescence recovery are shown on the right (b). N=8. Error bars: SEM. t test: ns: not significant, p=0.017(*).
(c, d) Images of FM 1-43 labeling (c) (arrows indicate FM 1-43 accumulations) and quantification of the number of FM 1-43 accumulations per boutonic area (d) at third instar larval synaptic boutons in sky mutants (yw eyFLP; FRT40A sky1:FRT40A sky2) expressing wild type GFP-Sky (using nSybGal4 (SkyWT); in sky mutants expressing GFP-SkyR79C using nSybGal4 (SkyR79C) and in sky mutants heterozygous for synaptojanin (sky1 synj1/FRT40A sky2) and expressing GFP-SkyR79C using nSybGal4 (synj+/−; SkyR79C). N=10 NMJs from 5 animals. Scale bar: 2 μm. Error bars: SEM. t test: ns: not significant, p=0.0027 (**).
(e) Quantification of the number of flies (genotypes in (c, d)) standing when incubated at 36° C. for the indicated time. N=40 (SkyWT); N=20 (SkyR79C) and N=30 (synj+/−; SkyR79C). Error bars: SEM.
(f) Quantification of the number of flies that fail to stand within a 5 s period following a 10 s vortex (seizuring flies). Male flies of the genotypes indicated in (c, d) are included. N=5; Error bars: SEM; t test: ns: not significant, p<0.01 (**).
Quantification of seizuring skyR79C flies for control or mock-treated flies (upper bar), Miltefosine fed flies at 50 μg/mL (middle bar) or at 100 μg/mL (lower bar) after 2 days of drug feeding (left panel), or 8 days of drug feeding (right panel). The percentage of flies that was active, in rest, or sitting still was analysed for all treatments for n=20 flies. Treatment with a high, probably toxic, concentration of 100 μg/mL did not lead to significant difference in seizure-behavour (n.s, non-significant) as compared to the control population, whereas a treatment with 50 μg/mL Miltefosine resulted in a significant rescue of seizure-like behaviour with p<0.001 (***) after 2 days of treatment and p<0.1 (*) still after 8 days of treatment.
Quantification of seizuring skyR79C flies for control or mock-treated flies and Drug-treated flies fed with Perifosine (A), Edelfosine (B), and Erufosine (C), for a daily administration at a concentration of 1000 μg/mL Perifosine, 500 μg/mL Edelfosine, and 400 or 1000 μg/mL Erufosine over 8 days of drug feeding. The fraction of seizuring flies was analysed for all treatments for n=10 flies at each timepoint.
The optimized Malachite Green assay was used to test the inhibitory capacity of the compounds, YU144118 as well as of the alkyl phospholipids Miltefosine, Perisofine, and Edelfosine, in the presence of the 5′-phosphatase domain of Synaptojanin-1 and IP3 as substrate. As compared to the negative (E+S) and DMSO (E+S+1% DMSO) negative controls, the compounds illustrated a complete inhibition of the activity when analysed after 1 h of measurement and subtracting of the background signal due to the presence of the compound at time point zero (E=5′-phosphatase domain of Synaptojanin-1; S=IP3).
The present invention will be described with respect to particular embodiments and with reference to certain drawings but the invention is not limited thereto but only by the claims. Any reference signs in the claims shall not be construed as limiting the scope. Of course, it is to be understood that not necessarily all aspects or advantages may be achieved in accordance with any particular embodiment of the invention. Thus, for example those skilled in the art will recognize that the invention may be embodied or carried out in a manner that achieves or optimizes one advantage or group of advantages as taught herein without necessarily achieving other aspects or advantages as may be taught or suggested herein. The invention, both as to organization and method of operation, together with features and advantages thereof, may best be understood by reference to the following detailed description when read in conjunction with the accompanying drawings. The aspects and advantages of the invention will be apparent from and elucidated with reference to the embodiment(s) described hereinafter. Reference throughout this specification to “one embodiment” or “an embodiment” means that a particular feature, structure or characteristic described in connection with the embodiment is included in at least one embodiment of the present invention. Thus, appearances of the phrases “in one embodiment” or “in an embodiment” in various places throughout this specification are not necessarily all referring to the same embodiment, but may. Similarly, it should be appreciated that in the description of exemplary embodiments of the invention, various features of the invention are sometimes grouped together in a single embodiment, figure, or description thereof for the purpose of streamlining the disclosure and aiding in the understanding of one or more of the various inventive aspects. This method of disclosure, however, is not to be interpreted as reflecting an intention that the claimed invention requires more features than are expressly recited in each claim. Rather, as the following claims reflect, inventive aspects lie in less than all features of a single foregoing disclosed embodiment.
Where an indefinite or definite article is used when referring to a singular noun e.g. “a” or “an”, “the”, this includes a plural of that noun unless something else is specifically stated. Where the term “comprising” is used in the present description and claims, it does not exclude other elements or steps. Furthermore, the terms first, second, third and the like in the description and in the claims, are used for distinguishing between similar elements and not necessarily for describing a sequential or chronological order. It is to be understood that the terms so used are interchangeable under appropriate circumstances and that the embodiments, of the invention described herein are capable of operation in other sequences than described or illustrated herein. The following terms or definitions are provided solely to aid in the understanding of the invention. Unless specifically defined herein, all terms used herein have the same meaning as they would to one skilled in the art of the present invention. Practitioners are particularly directed to Sambrook et al., Molecular Cloning: A Laboratory Manual, 4th ed., Cold Spring Harbor Press, Plainsview, N.Y. (2012); and Ausubel et al., Current Protocols in Molecular Biology (Supplement 114), John Wiley & Sons, New York (2016), for definitions and terms of the art. The definitions provided herein should not be construed to have a scope less than understood by a person of ordinary skill in the art.
“About” as used herein when referring to a measurable value such as an amount, a temporal duration, and the like, is meant to encompass variations of ±20% or ±10%, more preferably ±5%, even more preferably ±1%, and still more preferably ±0.1% from the specified value, as such variations are appropriate to perform the disclosed methods.
“Orthologues” are genes from different organisms that have originated through speciation, and are also derived from a common ancestral gene.
“Compound” or “test compound” is used herein in the context of a “drug candidate compound” and means any chemical or biological compound, including simple or complex organic and inorganic molecules, peptides, peptido-mimetics, proteins, antibodies, carbohydrates, nucleic acids or derivatives thereof.
The term “subject”, “individual” or “patient”, used interchangeably herein, relate to any organism for whom therapy or prophylaxis is desired, such as a vertebrate, particularly any mammal, including both a human and another mammal, e.g., an animal such as a rodent, a rabbit, a cow, a sheep, a horse, a dog, a cat, a lama, a pig, or a non-human primate (e.g., a monkey). However, it will be understood that the aforementioned terms do not imply that symptoms are present.
“Synaptic vesicles” or “neurotransmitter vesicles” are defined as small secretory vesicles that contain a neurotransmitter, and are naturally abundantly present organelles of a uniform size inside an axon near the presynaptic membrane. In physiological context, when a nerve impulse moves down the axon of a neuron and arrives at an axon terminal, it stimulates synaptic vesicles in the terminal to discharge neurotransmitters, a mechanism also called “synaptic vesicle trafficking”. After fusion with the membrane, a synaptic vesicle releases its contents into the synaptic cleft69.
The invention relates to a previously uncharacterized phosphoinositide binding pocket that docks the unconventional TBC protein Skywalker/TBC1D24 to synaptic membranes and is mutated in patients that suffer from diseases such as DOORS syndrome and epilepsy. The direct association of a TBC domain with membrane-phosphoinositides has, to the best of our knowledge, not yet been described and we showed that this feature is important for normal Skywalker function. Indeed, flies that express phosphoinositide-binding pocket mutants display presynaptic vesicle trafficking defects and seizure-like behaviour, demonstrating the essential role of phosphoinositide dependent membrane association and vesicle trafficking in TBC1D24-induced neuronal pathology.
Loss of function mutations in human TBC1 D24 lead to several disorders, referred to in the present invention as “TBC1D24-associated disorders”, such as severe forms of epilepsy (early onset epilepsy, familial infantile myoclonic epilepsy (FIME), focal epilepsy, dysarthria, myoclonic epilepsy with dystonia, familial malignant migrating partial seizures of infancy, De Flippo malignant migrating partial seizures of infancy), variable degrees of intellectual disability, hearing loss (nonsyndromic deafness, autosomal-dominant nonsyndromic hearing loss, and dominant nonsyndromic hearing impairment), and cortical myoclonus and cerebellar ataxia, DOORS syndrome (deafness, onychodystrophy, osteodystrophy, mental retardation and seizures)1-14,29. Although the number of mutations in TBC1D24 associated with these disorders is rapidly increasing, the molecular mechanisms underlying pathology remain concealed.
The surprising effect that Sky cationic pocket mutants harbor lower 4- and 5-phosphorylated phosphoinositide binding affinity raised the opportunity to try rescue the defects associated with the pathological cationic pocket mutants via increasing phosphorylated phosphoinositide levels (e.g. PI(4,5)P2 and PI(3,4,5)P3). Several methods can be applied to come to such an effect. In fruit flies, genetic ablation of Synaptojanin, a synaptically enriched phosphoinositide phosphatase, was reduced by 50% to result in lower mobility of the most severe Sky cationic pocket mutant back to wild type Sky levels and also rescue the neurological defects in the Sky mutant flies. The Synaptojanin-1 protein contains a Sac1 phosphatase domain and a 5′ phosphatase domain. The latter domain dephosphorylates, among others, PI(4,5)P2 and PI(3,4,5)P3. Based on the results obtained in the study leading to this invention, specific inhibitors of phosphoinositide phosphatases, such as the Synaptojanin-1 5′ phosphatase domain, are beneficial to revert TBC/D24-mutation associated defects. Other ways to obtain such an effect are accomplished by treatment with said inhibitors, leading to increased PI(4,5)P2 levels in a cell. Additionally, inhibitors affecting both, PI(4,5)P2 and PI(3,4,5)P3 levels would then also lead to rescue of TBC1D24-associated disorders in neuronal cells.
In a first aspect, the invention relates to a phosphoinositide (PI) phosphatase inhibitor to increase phosphatidylinositol 4,5-bisphosphate (PI(4,5)P2) and/or PI(3,4,5)P3 levels in a cell, for use in treatment of TBC1D24-associated disorders. The term “inhibitor” refers to any molecule or compound that is capable of blocking or reducing the activity of in this case, a PI phosphatase enzyme. Said inhibitor might be a “small molecule compound”, which refers to a low molecular weight (e.g., <900 Da or <500 Da) organic compound. The term “treatment” or “treating” or “treat” can be used interchangeably and is defined by a therapeutic intervention that slows, interrupts, arrests, controls, stops, reduces, or reverts the progression or severity of a sign, symptom, disorder, condition, or disease, but does not necessarily involve a total elimination of all disease-related signs, symptoms, conditions, or disorders. A particular embodiment relates to the PI phosphatase inhibitor, for use in treatment of TBC1D24-associated disorders, wherein said TBC1D24-associated disorders comprise severe forms of epilepsy (early onset epilepsy, familial infantile myoclonic epilepsy (FIME), focal epilepsy, dysarthria, myoclonic epilepsy with dystonia, familial malignant migrating partial seizures of infancy, De Flippo malignant migrating partial seizures of infancy), variable degrees of intellectual disability, hearing loss (nonsyndromic deafness, autosomal-dominant nonsyndromic hearing loss, and dominant nonsyndromic hearing impairment), cortical myoclonus and cerebellar ataxia, and DOORS syndrome (deafness, onychodystrophy, osteodystrophy, mental retardation and seizures). Alternatively, said small molecule compound for use in TBC1D24-associated disorders is a compound for use in severe forms of epilepsy (early onset epilepsy, familial infantile myoclonic epilepsy (FIME), focal epilepsy, dysarthria, myoclonic epilepsy with dystonia, familial malignant migrating partial seizures of infancy, De Flippo malignant migrating partial seizures of infancy), variable degrees of intellectual disability, hearing loss (nonsyndromic deafness, autosomal-dominant nonsyndromic hearing loss, and dominant nonsyndromic hearing impairment), cortical myoclonus and cerebellar ataxia, or DOORS syndrome (deafness, onychodystrophy, osteodystrophy, mental retardation and seizures). More particular, said TBC1D24-associated disorder is refractory epilepsy or DOORS.
Phosphoinositides (PIs) are a group of key signaling and structural lipid molecules involved in a myriad of cellular processes. PI phosphatases, together with PI kinases, are responsible for the conversion of PIs between distinctive phosphorylation states. PI phosphatases are a large collection of enzymes that are evolved from at least two disparate ancestors. For a review on phosphoinositide phosphatase structural insights, see Hsu and Mao (Biochim Biophys Acta. 2015; 1851(6): 698-710). One group of PI phosphatases is distantly related to endonucleases, which applies divalent metal ions for phosphoryl transfer. The other group is related to protein tyrosine phosphatases, which contains a highly conserved active site motif Cys-X5-Arg (CX5R). Based on catalytic mechanisms, PI phosphatases can be categorized into two major classes. One class is the inositol polyphosphate 5-phosphatases, which are Mg2+-dependent phosphatases comprising 10 mammalian and 4 yeast members. 5-phosphatases have a characteristic central catalytic domain that exhibits sequence homology to the apurinic/apyrimidic family of endonucleases. Members of this class hydrolyze the D5 phosphate of the inositol ring of both soluble inositol polyphosphates and membrane-bound PIs. The other class is characteristic of a highly conserved CXSR active site motif, of which the cysteine residue functions as the nucleophile while the arginine residue positions the scissile phosphate group. Based on their primary sequences, enzymes in this class can be further divided into four sub-families that include the Sac1 domain containing phosphatase, PTEN, myotubularin, and 4-phosphatase.
The inositol polyphosphate 5-phosphatases are a group of Mg2+-dependent phosphatases first characterized in studies on the metabolism of the inositol phosphate second messenger Ins(1,4,5)P3. One example of the 5-phosphatase is synaptojanin 1 (SYNJ1) which was discovered to be responsible for the hydrolysis of PI(4,5)P2 on synaptic vesicles at the nerve terminal. Besides the 5-phosphatase domain, SYNJ1 and SYNJ2 share an N-terminal Sac1 domain, which was later found to be a member of a new family of PI phosphatases.
So the inhibitors of phosphoinositide phosphatases can be determined in a biochemical assay using a PI phosphatase enzyme and PI substrate.
The terms “blocking”, “inhibiting”, or “reducing” an enzymatic activity are used interchangeably and mean the observed degree of the catalytic activity is significantly lower in comparison to the catalytic activity observed in the absence of the compound. With significantly lower, it is meant that the activity is reduced preferably, but not by way of limitation, with at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 99%, or at least about 100%.
The terms “stimulating” or “increase”, an enzymatic activity or PI(4,5)P2 levels are used interchangeably and mean the observed degree of the catalytic activity or degree of increased levels is significantly higher in comparison to the catalytic activity or level observed in the absence of the compound. With significantly higher, it is meant that the activity or level is increased preferably, but not by way of limitation, with at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 99%, or at least about 100%.
In one embodiment, the present invention provides phosphoinositide phosphatase inhibitors or inhibiting compounds to increase PI(4,5)P2 levels in a cell, for use in treatment of said TBC1D24-associated disorders, wherein said inhibitors modulate molecules involved in PI metabolism and are specifically effective in increasing 4- and 5-phosphorylated phosphoinositides, including PI(4,5)P2 and/or PI(3,4,5)P3 levels by preferably, but not by way of limitation, at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about >90%. Specifically, said increased PI(4,5)P2 or PI(3,4,5)P3 levels are detectable by an assay system known by a person skilled in the art, comprising, for instance but not limited to, detection of labeled PI(4,5)P2 and/or PI(3,4,5)P3 such as for instance BODIPY-labeled PI(4,5)P2 and/or PI(3,4,5)P3 as described61, or other fluorescent63 or radioactive-labeled assays62, or alternative Pi-sensors. Said increased PI(4,5)P2 levels are in addition detectable by, for instance but not limited to, PI(4,5)P2-interacting proteins domains (such as PLCd1PH or Tubby) fused to a fluorescent probe such as eGFP66,67 or by using PI(4,5)P2-specific antibodies68.
Another embodiment provides PI phosphatase inhibitors to increase PI(4,5)P2 levels in a cell for use in treatment of said TBC1D24-associated disorders, wherein said inhibition is accomplished herein for any small molecule compound that is capable of blocking or reducing the activity of said PI phosphatase enzymes, i.e. hydrolases belonging to the type II inositol polyphosphate 5-phosphatase and to class EC 3.1.3.36 and catalyzing the dephosphorylation of 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate (PI(4,5)P2) resulting in 1-phosphatidyl-1D-myo-inositol 4-phosphate (P(4)IP) and free phosphate. Specifically, said phosphatase activity is for instance detectable by a biochemical assay as known by a person skilled in the art, comprising, but not limited to, measurement of release of phosphate, such as the Malachite Green assay60 or PiPer Phosphate Assay Kit (Life Technologies, NY), to measure phosphatase activity. Alternatively, PI phosphatase inhibitors or compounds increasing PI(3,4,5)P3 levels could also affect TBC1D24/Skywalker, and therefore be considered as therapeutic agents for use in TBC1D24-associated disorders.
In other embodiments, said inhibitor may, for example and not by way of limitation, inhibit the activity of phosphatidylinositol-3-kinases, stimulate the activity of phosphatidylinositol protein kinase 1 gamma (PIPK1γ), inhibit the activity of phospholipase C (PLC), or increase the activity of phosphatidylinositol-3,4,5-trisphosphate 3-phosphatases such as PTEN to increase PI(4,5)P2 levels. Without limitation, desired effects of the present invention on a treated subject include, in addition to increased PI(4,5)P2, re-establishing of the TBC1D24 protein mobility via membrane association, and/or a rescue of TBC1D24-associated disorders/symptoms.
In a specific embodiment, said PI phosphatase inhibitor or compound for use in treatment of said TBC1D24-associated disorders, is identified in a biochemical assay, for instance but not limited to, the Malachite Green assay using a PI phosphatase enzyme (e.g. see Example 11).
In another aspect of the invention, the PI phosphatase inhibitor increases the PI(4,5)P2 levels in a cell via Synaptojanin-1 inhibition. More particular, Synaptojanin-1 is the polyphosphatidylinositide or polyphosphoinositide phosphatase concentrated in presynaptic nerve terminals, where it dephosphorylates a pool of phosphatidylinositol 4,5-bisphosphate implicated in synaptic vesicle recycling.
As exemplified, by inhibition of Synaptojanin activity in fruit flies, Sky/TBC1D24-membane interactions were re-established, which provides the molecular insight and consecutive approach to develop viable strategies to bypass the Sky/TBC1D24-induced defects based on Synaptojanin-1 phosphatase inhibition, which involves an increase of PI(4,5)P2 levels. Moreover, in one embodiment, said increase in PI(4,5)P2 levels is obtained by Synaptojanin-1 5′ phosphatase domain activity inhibition, as said domain enables the removal of a phosphate group from PI(4,5)P2. The N-terminal Sac1 domain predominantly dephosphorylates PI(3)P and PI(4)P, whereas the 5′ phosphatase domain dephosphorylates PI(4,5)P2 and PI(3,4,5)P3 at the 5′ position of the inositol ring. Hydrolysis of PI(4,5)P2 is potentially involving both domains in a concerted way, as the 5′ phosphatase domain first converts PI(4,5) P2 to PI(4)P, which is directly channelled to Sac1 catalytic reaction for further dephosphorylation to PI without accumulation of the intermediate. In a particular embodiment accumulation of PI(4,5)P2 is obtained by inhibition of the 5′ phosphatase domain of Synaptojanin-1, for use in treatment of TBC1D24-associated disorders.
On the other hand, like other proteins with a role in endocytosis, Synaptojanin-1 undergoes constitutive phosphorylation mediated by cyclin-dependent kinase 5 (CDK5) in resting synapses and stimulation-dependent dephosphorylation by calcineurin, thereby regulating its function both in vitro and in intact synaptosomes. It was shown that Cdk5 phosphorylation inhibited the inositol 5-phosphatase activity of Synaptojanin-1, whereas dephosphorylation by calcineurin stimulated such activity64. Therefore the activation of CDK5 by said compounds is in one embodiment also crucial in the regulation of PI(4,5)P2 turnover at synapses.
In an alternative embodiment, said increase in PI(4,5)P2 level is obtained with a compound, wherein said compound inhibits phosphatidylinositol-3-kinases, for use in treatment of TBC1D24-associated disorders. Said phosphatidylinositol-3-kinase, is characterized in that this enzyme is a phosphor-transferase belonging to the class I phosphatidylinositol-4,5-bisphosphate 3-kinases (EC 2.7.1.153), converting PI(4,5)P2 into PI(3,4,5)P3 using ATP.
Another embodiment of the present invention relates to inhibitors to increase PI(4,5)P2levels for use in treatment of TBC1D24-associated disorders, wherein said increase is obtained by phospholipase C (PLC) inhibition. PLC cleaves PI(4,5)P2, which is a phospholipid, into diacyl glycerol (DAG) and inositol 1,4,5-trisphosphate (IP3). Thus PLC has a profound impact on the depletion of PI(4,5)P2, acting as a membrane anchor, and is critical to the regulation of local PI(4,5)P2 concentrations within plasma and nuclear membrane.
In a particular embodiment, said inhibitors to increase said PI(4,5) P2 levels for use in treatment of TBC1D24-associated disorders, are characterized in that said PI(4,5)P2 levels are increased in neuronal cells, wherein neuronal cells or neurons are a type of cell in the central nervous system, which receive, integrate, and pass along information by releasing neurotransmitters. Related to the increase of PI(4,5)P2 levels, compounds or PI phosphatase inhibitors leading to increased PI(3,4,5)P3 levels in neuronal cells would be considered for use in treatment of TBC1D24-associated disorders as well. Neurotransmitters are chemicals that cross-over from the terminal button at the end of an axon over the synapse to the neighbouring neuron. Non-limiting examples of neuron cells are primary cortical neurons, primary basal forebrain cholinergic neurons, primary neural stem cells, sensory neurons (e.g. retinal cells, olfactory epithelium cells), motoneurons (e.g. spinal motor neurons, pyramidal neurons, Purkinje cells) and interneurons (e.g. dorsal root ganglia cells).
Another embodiment of the invention relates to a PI phosphatase inhibitor, for use in treatment of TBC1D24-associated disorders, characterized in that said inhibitor is selected from a list consisting of bpV(pic), perifosine, edelfosine, miltefosine, erufosine, or YU144118, or a derivative thereof, wherein a derivative means any compound produced from one of said listed original compounds either directly or by modification or partial substitution of the original compound core, by a chemical reaction, resulting for instance in a salt, or a hydrate.
In one embodiment of the present invention, the PI phosphatase inhibitor, for use in treatment of TBC1D24-associated disorders, is an alkyl phospholipid. Synthetic Alkyl phospholipids or ether lipids are lipids in which one or more of the carbon atoms on glycerol is bound to an alkyl chain via an ether linkage, as opposed to the usual ester linkage. Several clinically relevant alkyl phospholipid compounds have been developed (e.g.
One embodiment provides the alkyl phospholipid compound inhibitor, for use in treatment of TBC1D24-associated disorders, wherein said alkyl phospholipid is miltefosine, or a derivative thereof. In particular, the invention provides the use of miltefosine or a derivative thereof, at a concentration that increases PI(4,5)P2for use in treatment of TBC1D24-associated disorders, with potential for a novel therapeutic application for said drug compound, also launched as the first approved drug for cutaneous or mucosal leishmaniasis via oral administration as Impavido (and Miltex), owned by Zentaris GmbH (Aeterna), and launched as well as a breast cancer therapy by ASTA Medica Oncology (now Baxter Oncology). Another embodiment relates to the alkyl phospholipid compound inhibitor for use in treatment of TBC1D24-associated disorders, wherein said compound is perifosine, or a derivative thereof. Perifosine may be administered to achieve a local concentration in the area of cells to be treated or to increase local PI(4,5)P2 through inhibition of PLC, or through inhibition of PI phosphatase activity, and preferably resulting in decrease in TBC1D24-associated disorder symptoms. Alternatively, the alkyl phospholipid compound for use in treatment of TBC1D24-associated disorders, is edelfosine, or a derivative thereof. Or the alkyl phospholipid compound, for use in treatment of TBC1D24-associated disorders, is erufosine, or a derivative thereof, a compound known to allow BBB crossing. Furthermore, in another embodiment, the invention provides for the use of bpV(pic) or a derivative thereof, known in the art to block phosphatidylinositide phosphatase activity, thereby in a preferred embodiment increasing PI(4,5)P2 levels for use in treatment of diseases concerning pathological TBC1D24 mutations. Another embodiment for the present invention provides YU144118 or a derivative thereof as a compound selected from the list of compounds for use in treatment of TBC1D24-associated disorders, wherein YU144118 is known to inhibit phosphatidylinositide phosphatase activity65, revealing a potent inhibitor leading to increase in PI(4,5)P2 in a cell.
In one embodiment, said PI phosphatase inhibitors are analysed in flies for behavioural rescue phenotypes, such as flight and seizure assay (see Examples). In another embodiment, further confirmation of these observations is done by feeding Sky1/2 mutants expressing SkyR79C with PI(4,5) P2 increasing compounds, resulting in normal GFP SkyR79C mobility in the FRAP assay, indicating that increasing the PI(4,5)P2 levels restricts the diffusion of the GFP-SkyR79C mutant at synapses. Furthermore, while expression of the SkyR79C mutant in sky1/2 flies could only partially reduce the number of FM 1-43 accumulations, PI(4,5)P2 stimulating compound feeding rescues the FM 1-43 accumulation defect, and no significant difference from controls (yw; FRT40A) or sky1/2 mutants expressing wild type SkyWT would be observed.
In another embodiment, human embryonic stem cells (H9) are mutated using CRISPR/CAS9 technology in the TBC1D24 positive pocket encoding residue. The mutated cells are allowed to differentiate further into glutamatergic cortical neurons, followed by transfection with a lentivirus expressing synaptophluorin. Synaptophluorin allows measurement or synaptic vesicle fusion rates, which is a disrupted parameter in fly sky mutants. A second measurement of the synaptic vesicle fusion rate when stimulating the neurons at high frequency (field stimulation) in the absence and presence of PI(4,5)P2 stimulating compounds further allows to identify the impact of each compound or PI phosphatase inhibitor tested.
In a second aspect, a method for producing a PI phosphatase inhibitor compound, characterized in that said inhibitor is a 5′ phosphatase domain-specific Synaptojanin-1 inhibitor, wherein said method comprises the steps of: a) providing an in vitro system comprising the Synaptojanin-1 5′ phosphatase domain protein as depicted in SEQ ID NO:1 or a homologue with at least 95% amino acid identity thereof and PI(4,5)P2 or PI(3,4,5)P3 substrates, or derivatives thereof; b) administering a test compound to said in vitro system; c) monitoring phosphatase activity in said in vitro test system, wherein, a reduction in said phosphatase activity as compared to phosphatase activity measured under the same test conditions in the same system without the test compound, identifies said test compound as a Synaptojanin-1 inhibitor, more particular a 5′ phosphatase-specific Synaptojanin-1 inhibitor. Said method provides inhibitors or compounds for use in treatment of TBC1D24-associated disorders.
Said “in vitro system” refers to a system comprising at least the necessary components and environment to execute said method, and makes use of biological molecules, organisms, a cell (or part of a cell) outside of their normal naturally-occurring environment, permitting a more detailed, more convenient, or more efficient analysis than can be done with whole organisms. Non-limiting examples of said in vitro system as described herein are neuronal cells, induced pluripotent stem cells (also known as iPS cells or iPSCs), or a buffer condition suitable to perform said monitoring assay. The substrates provided in said in vitro system, PI(4,5)P2 or PI(3,4,5)P3, or derivatives thereof include labelled, tagged or any other form of PI(4,5)P2 or PI(3,4,5)P3 derivatives that provide an advantage to the assay, e.g. in detecting, quantifying, or visualizing the substrates.
In one embodiment, said method provided in step a) by said in vitro system also contains the Synaptojanin-1 5′ phosphatase domain protein as depicted in SEQ ID NO:1 or a homologue with at least 95% amino acid identity thereof. In another embodiment, said method provided in step a) by said in vitro system contains Synaptojanin-1 Sac1-domain inactivated mutant protein as depicted in SEQ ID NO:2 or a homologue with at least 95% amino acid identity thereof, instead of the Synaptojanin-1 5′ phosphatase domain protein as depicted in SEQ ID NO:1 or a homologue with at least 95% amino acid identity thereof.
“Homologue” or “Homologues” of a protein encompass peptides, oligopeptides, polypeptides, proteins and enzymes having amino acid substitutions, deletions and/or insertions relative to the unmodified protein in question and having similar biological and functional activity as the unmodified protein from which they are derived. According to the present invention, the degree of identity between a given reference amino acid sequence and an amino acid sequence which is a variant of said given amino acid sequence will preferably be at least about 95%, 96%, 97%, 98%, or 99%. The degree of identity is given preferably for an amino acid region which is at least about 90% or about 100% of the entire length of the reference amino acid sequence. For example, if the reference amino acid sequence consists of 200 amino acids, the degree of identity is given preferably for at least about 180, or about 200 amino acids, preferably continuous amino acids. In preferred embodiments, the degree/percentage of identity is given for the entire length of the reference amino acid sequence. The term “amino acid identity” as used herein refers to the extent that sequences are identical on an amino acid-by-amino acid basis over a window of comparison. Thus, a “percentage of sequence identity” is calculated by comparing two optimally aligned sequences over the window of comparison, determining the number of positions at which the identical amino acid residue (e.g., Ala, Pro, Ser, Thr, Gly, Val, Leu, Ile, Phe, Tyr, Trp, Lys, Arg, His, Asp, Glu, Asn, Gln, Cys and Met) occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison (i.e., the window size), and multiplying the result by 100 to yield the percentage of sequence identity. The alignment for determining sequence identity, can be done with art known tools, preferably using the best sequence alignment, for example, using CLC main Workbench (CLC bio) or Align, using standard settings, preferably EMBOSS::needle, Matrix: Blosum62, Gap Open 10.0, Gap Extend 0.5.
Accordingly, the invention relates to the use of SEQ ID NO: 1-defined Synaptojanin-1 5′ phosphatase domain protein sequence, and/or the use of SEQ ID NO: 2-defined Synaptojanin-1 Sac1-domain inactivated mutant protein sequence, thereby providing a suitable system for the test compounds to identify 5′ phosphatase domain-specific Synaptojanin-1 inhibitors.
In one embodiment, monitoring of said PI phosphatase activity in said method for producing said 5′ phosphatase domain-specific Synaptojanin-1 inhibitors, is characterized in that release of phosphate is detected. Such a measurement can be done in different embodiments in several ways65, for example, but non-limiting, via the malachite green assay60 or PiPer Phosphate Assay Kit (Life Technologies, NY), or detection of labeled PI(4,5)P2 such as for instance BODIPY-labeled PI(4,5)P2 as described61, or other fluorescent63 or radioactive-labeled assays62, or using alternative Pi-sensors.
In other embodiments, monitoring of said PI phosphatase activity are performed by, for instance but not limited to, PI(4,5)P2-interacting proteins domains (such as PLCd1PH or Tubby) fused to a fluorescent probe such as eGFP 66,67 or by using PI(4,5)P2-specific antibodies68.
Said monitoring will result in identification of a hit compound when reduced phosphatase activity is observed as compared to a sample without test compound, wherein said reduction is preferably, but not by way of limitation, at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 99%, or at least about 100%.
It is to be understood that although particular embodiments, specific configurations as well as materials and/or molecules, have been discussed herein for compounds and methods according to the present invention, various changes or modifications in form and detail may be made without departing from the scope and spirit of this invention. The following examples are provided to better illustrate particular embodiments, and they should not be considered limiting the application. The application is limited only by the claims.
1. The Crystal Structure of the Skywalker TBC Domain Reveals an Unanticipated Cationic Pocket
To determine the crystal structure of the TBC domain of Skywalker (Sky1-353) the protein was expressed in E. coli and purified to homogeneity. X-ray diffraction data for crystals of the native protein were collected at 2.5 Å resolution (Table 1). Given the relatively low sequence identity of Sky1-353 compared to other TBC domains for which the structure is available, the structure was solved via single-wavelength anomalous diffraction (SAD) on a selenomethionine-derivative. The asymmetric unit of the crystal contains one copy of Sky1-353, and clear electron density is present for most of the peptide chain and side chains. Only the N-terminal regions spanning residues 1-26 and 37-54 as well as the last residue (353) are not modelled due to lack of electron density. Sky1-353 superimposes well with the eleven known TBC domain-containing proteins in the PDB (rmsd values in the range of 2.3 to 3.3 ÅA2 over ˜230 aligned residues). Similar to other TBC domains, Sky1-353 is all-helical and can be divided into an N-terminal and a C-terminal lobe27 (
To identify additional unique features of the Sky TBC domain we calculated the conservation scores of the amino acid residues with the Consurf algorithm and using an alignment of 250 Sky homologs containing a TBC and a TLDc domain28. The most striking feature is a region of high conservation at the interface of the N-terminal and C-terminal lobe on the opposite side of the GTPase binding surface (
a 5% of the reflections are used for the Rfree calculation.
2. DOORS-Associated Mutations in TBC1D24 Map to the Cationic Pocket
Mutations in TBC1D24 cause epilepsy, DOORS syndrome and non-syndromic deafness. To gain insight into the mechanisms of pathology we mapped the pathogenic mutations14 on the structure. 19 of the 24 different known mutations are missense mutations and most of them are located in the TBC domain of TBC1D24. Sequence alignment of TBC1D24 and Sky allows us to map 14 of these 19 residues on the structure (
The majority (70%) of DOORS syndrome patients with lesions in TBC1D24, carry mutations in either one of two arginine residues, R40 and R24213. These residues cluster together in the crystal structure (R79 and R281, using Sky numbering) and are central to the positively charged pocket in the Sky1-353 structure. Moreover, a third R residue that has been found mutated in non-syndromic deafness patients (R293 in TBC1D24—R335 in Skywalker) also maps to the same positively charged pocket29. These observations further underpin the importance of the cationic pocket and its significance in TBC1D24-related disease.
3. The cationic pocket in Skywalker is a Previously Uncharacterized Phosphoinositide-Binding Module
TBC1D24 and Skywalker regulate vesicle trafficking, a process that requires membrane interactions20,24,30. We therefore hypothesized that the positively charged pocket of Sky serves as a binding module to negatively charged membranes. We used a liposome flotation assay and mixed Sky1-353 with liposomes produced from Folch-extracted total brain lipids and centrifuged the sample in a sucrose gradient. After recovering six fractions from the top to the bottom of the centrifugation tube we find that Sky1-353 is present in the top fractions that contain the liposomes. By contrast, Sky1-353 is largely absent from the bottom fractions that do not contain liposomes (
To obtain a quantitative estimate of the affinity of Sky1-353 for PI(4,5)P2, we determined the thermal stability (melting temperature, Tm) of Sky1-353 in the presence of increasing amounts of inositol 1,4,5-trisphosphate (IP3), the soluble head group of PI(4,5)P2, using thermal shift assays34. To ensure the positive pocket in Sky was devoid of any ligand prior to performing this experiment we extensively dialyzed the protein against sulfate ion-free buffer. A saturating (2 mM) concentration of IP3 increases the Tm of Sky1-353 by about 13° C. Plotting the Tm value versus the IP3 concentration yields a binding curve that can be fitted to a quadratic equation yielding a binding dissociation constant (KD) of 19±3 μM (
To provide molecular insight into the mode of phosphoinositide binding by Sky we determined the crystal structure of Sky1-353 in complex with IP3. We solved the structure of this complex by molecular replacement using the Sky1-353 structure as a model and refined it to a resolution of 2.30 Å (Table 1). No major conformational changes occur between the structures of Sky1-353 (PDB SHJN) and Sky1-353-IP3 (PDB 5HJQ). The structure shows very clearly defined electron density for the IP3 molecule in the positively charged pocket of the TBC domain and we were able to unambiguously assign the phosphates to positions 1, 4 and 5 of the inositol ring (
4. Analogs to Pathogenic Mutations Lower Phosphoinositide Binding Affinity in Sky
To determine if pathogenic mutations in the positive pocket of TBC1D24 affect phosphoinositide binding we assessed the binding of mutant Sky1-353 proteins to liposomes containing PI(4,5)P2. We created and purified the R79C, R281C and R335P mutants that correspond to the R40C, R242C and R293P mutations in TBC1D24 patients (
(2% PI(4,5)P2) and more (0.5% PI(4,5)P2) stringent conditions. Both the R79C and 3Glu mutation completely disrupt the interaction with PI(4,5) P2 (
Subsequently, the effect of the pathogenic point mutations was further quantified by measuring the affinity for IP3 using thermal shift assays. The thermal stability of the R79C and R281C mutants in absence of ligands (Tm=32° C.) is somewhat lower compared to the wild type protein (Tm=34° C.) and the R335P mutant (Tm=35° C.). While the presence of a saturating amount of IP3 causes a thermal stability shift of 13° C. in wild type Sky1-353, the R79C and R281C mutants show only a small increase in thermal stability by 4° C. and the R335P mutant by 8° C. Fitting of the titration curves yields a Kd of 325±200 μM for R79C, 180±100 pM for R281C and 67±17 μM for R335P, compared to a Kd of 19±3 μM for the wild type protein (
5. The Cationic Pocket Restricts Sky Mobility at Synapses In Vivo
Sky is prominently present at synapses where it regulates the trafficking of synaptic vesicles20, a process intimately connected to vesicle's phosphoinositide composition32. In this respect, we reasoned that binding to phosphoinositides in the membrane could be critical for Sky to exert its function and we hypothesized that in vivo, the ability of Sky to bind to membranes would restrict its diffusion. To test Sky mobility at synapses we turned to Drosophila neuromuscular junctions (NMJs) and assessed the recovery of GFP fluorescence after photobleaching of wild type and mutant GFP Sky (FRAP) (
6. The Cationic Pocket is Critical for Sky Function
PI(4,5)P2 and PI(3,4,5)P3 are present in (synaptic) membranes and are also critical during synaptic endocytosis33,37. Given that Sky regulates the trafficking of vesicles we wondered whether membrane binding is functionally relevant in vivo. We expressed wild type and mutant Sky in neurons (nSybGal4) of sky½ mutants and assessed vesicle trafficking. We stimulated the neurons in the presence of FM 1-43, a fluorescent dye that is internalized into newly endocytosed vesicles, and then imaged synaptic fluorescence. In sky½ mutants, FM 1-43 accumulates in sub boutonic membrane structures that previously20 were shown to harbor markers of sorting endosomes (FYVE-GFP, Rab5) (
In contrast, expression of the Sky point mutants (R79C, R281C and 3Glu) only partly rescues the defect in sky½ mutants, and several FM 1-43 accumulations are still present. Quantification of the data indicates that the conditions where we express mutant Sky in sky½ mutants are different from both controls (yw; FRT40A or sky½ expressing SkyWT: p<0.0001) and from sky½ mutants (p<0.0001) (
7. Pathogenic Cationic Pocket Mutations Cause Neurological and Epilepsy-Like Defects in Fruit Flies
Sky1/2 mutant flies expressing cationic pocket mutants display synaptic vesicle trafficking defects and patients containing the corresponding mutations suffer from epilepsy and other neuronal defects. We therefore assessed if the cationic pocket-mutant flies show behavioural defects as well. Sky null and severe hypomorphic mutants die during development, but expression of wild type Sky only in the nervous system rescues them to adulthood (
Temperature alters the strength of synaptic transmission in fruit flies and several synaptic transmission mutants and mutants that undergo seizures are also sensitive to changes in temperature. We find that sky1/2 mutants expressing Sky3Glu or SkyR79C lose coordination and some flies fail to stand when incubated at temperatures above 34° C. for more than 3 min (
Finally, to assess the behaviour of sky mutants that express Sky3Glu or SkyR79C under basal conditions we measured the activity of individual flies over a 24 h period (12 h light and 12 h dark). Activity is monitored in an automated fashion by assessing the interruption of an infrared light beam when flies are walking in horizontal tubes41. As shown in
8. Epilepsy-Like Defects Caused by Sky Cationic Pocket Mutations are Rescued by Partial Loss of Synaptojanin
Our findings underpin the importance of the cationic phosphoinositide-binding pocket for Sky function in the nervous system. We therefore tested if genetically increasing synaptic PI(4,5)P2 levels in vivo can rescue the defects associated with the Skywalker cationic pocket mutants. For this purpose we used mutations in synaptojanin that encodes a synapse-specific phosphoinositide phosphatase25,26,42. Compared to controls synaptojanin mutants harbor increased PI(4,5)P2 levels at synapses43. We find that heterozygous synaptojanin mutants very significantly rescue the cellular and behavioral defects associated with Sky positive pocket mutants (
9. Epilepsy-Like Defects Caused by Sky Cationic Pocket Mutations are Rescued by Treatment with a PI(4,5)P2 Stimulating Compound, the Alkyl Phospholipid Miltefosine, in Fruit Flies
To assure that stimulation of PI(4,5)P2 levels in vivo can rescue the defects associated with the Skywalker cationic pocket mutants (SkyR79C), a commercially available alkyl phospholipid compound, Miltefosine, with known impact on PI(4,5)P2 levels was tested for treatment of gender selected adult 4-7 day old sky1/2 flies with cationic pocket mutations. For drug feeding, 10-20 flies per treatment vial were maintained in a 12 h light and dark cycle to maintain circadian rhythm, while the analysis was performed on 5 flies per vial for flight, after acclimatization to the test chamber, and 10 flies per vial for stimulation or behavioural challenge by vortexing. In total n=20 flies were analyzed per treatment as well as for the control flies reared on normal food (mock-treated). The effect of Miltefosine (Sigma, M5571) daily administered in dyed food at 50 μg/mL or at 100 μg/mL was tested over a feeding period of 2 and 8 days of drug exposure, after which animal behaviour was analyzed via flight and seizure assays.
Compared to mock-treated controls, we found a significant rescue of the cellular and behavioural defects associated with Sky positive pocket mutants for Miltefosine treatment at 50 μg/mL, but not at 100 μg/m L, probably due to toxicity at the highest concentration (
10. Rescue Treatment in Fly Using Alkylphospholipid Compounds.
Perifosine (Sigma Aldrich, SML0612), Edelfosine (Sigma Aldrich, SML0332) and Erufosine (6d cpd, Alam et al., 2012. European J. Med. Chem. 47: 485-492.) also belong to the same class of PI(4,5)P2 stimulating compounds annotated as alkyl phospholipids, as Miltefosine is. Erufosine has furthermore been described as having the potential to cross the blood-brain-barrier (Van Blitterswijk and Verheij, 2013. Biochim. & Biophys. Acta, 1831:663-674). To confirm that alkyl phospholipids can rescue the defects associated with the Skywalker cationic pocket mutants (SkyR79C), those compounds have been incorporated in fly testing, by quantifying their seizure and flight activity.
Each data point represents averages of 10 animals tested over 8 days and analyzed per drug treatment as well as the control flies reared on normal food (mock-treated).
For drug treatment, a concentration range between 100 and 1000 μg/mL was tested for daily administration. A positive effect was observed for Perifosine daily administered in dyed food at a concentration of 1000 μg/mL, and for Erufosine daily administered in dyed food at a concentration between 400-1000 μg/mL. For Edelfosine, the treatment at a concentration of 500 μg/mL is shown in
Compared to mock-treated controls, we found a significant rescue of seizures, which are associated with Sky positive pocket mutants, for the alkyl phospholipid compounds after 8 days of treatment, although at different concentrations of administration (
11. In Vitro Screening Assay for Inhibition of the 5′-phosphatase Domain of Human Synj1
With the aim to in vitro screen compound libraries for potent Synj1 inhibitors specifically affecting the 5′-phosphatase domain activity, a robust enzymatic assay was used. First, an expression plasmid for the recombinant expression of the 5′-phosphatase domain of Synj1 (SEQ ID NO:1) was constructed. This protein was subsequently produced in high amounts and purified to homogeneity. A commercially available assay in a 96-well plate format is the Malachite Green Phosphate Assay Kit (BioAssay Systems).
Initial experiments using the 5′-phosphatase domain of Synj1 and inositol-3-phosphate (IP3) (Merck Millipore) as substrate showed clear 5′-phosphatase activity using the Malachite Green Phosphate assay according to the manufacturer's protocol. Moreover, addition of the inhibitor YU14411865 showed inhibition of the activity in a dose dependent way. After assay optimization, the assay is used to measure inhibitory activity of known compounds as well as to further allow a high-throughput setup for compound screening.
A number of compounds were analyzed to test their effect on the phosphatase activity of the 5′-phosphatase domain specifically. YU144118, as well as several alkyl phospholipids (Miltefosine, Perifosine and Edelfosine) were analyzed for their inhibitory activity in this assay. As shown in
Our biochemical and structural data show that Sky preferentially binds phosphoinositides that are phosphorylated in the 4- and 5-position, including PI(4,5)P2 and PI(3,4,5)P3. Similar to other phosphoinositide binding domains, the phosphoinositide-binding pocket of Sky is constituted primarily of arginine and lysine residues that interact via salt bridges with the phosphate groups and form a relatively shallow binding pocket. However, in contrast to the majority of previously characterized phosphoinositide-binding domains, the positively charged residues in the Sky TBC domain are provided by secondary structure elements from different regions in the amino acid sequence, such that a phosphoinositide-binding motif cannot be easily discerned from the primary sequence alone48. The binding specificity of Sky for 4- and 5-phosphorylated phosphoinositides, including PI(4,5)P2 and PI(3,4,5)P3, agrees with the physiological role of Sky in vesicular trafficking. Sky has been proposed to orchestrate the trafficking of synaptic vesicles at nerve terminals20,24,30, a process that requires the correct targeting of the protein to endocytic membranes thereby enabling local interactions to guide vesicle trafficking. Phosphoinositides phosphorylated at specific locations on the inositol ring serve as identity tags for specific membrane compartments, recruiting specific phosphoinositide-binding proteins31,50. PI(4,5)P2 and PI(3,4,5)P3 account for about 1% of the phospholipids in the inner leaflet of the plasma membrane and concentrate in endocytic and exocytic zones during synaptic vesicle cycling, allowing synaptic factors to bind and orchestrate vesicle formation and fusion37,51. Sky localizes to synapses20 and we show that mutations in the phosphoinositide-binding pocket significantly increase the mobility of Sky. These results, together with our observations that Sky binds lipid-membranes, suggest that the wild type protein associates with membranes in vivo. We propose that Sky is recruited to the synaptic membrane zones that are rich in PI(4,5)P2 and PI(3,4,5)P3. Binding at these membrane compartments can potentially be stabilized further by interactions with other membrane-bound partner proteins. Conversely, binding of Sky to the membrane could also recruit and regulate target GTPases or other regulators. These (transient) interactions can then potentially participate in regulating Skywalker-dependent synaptic vesicle trafficking. Given that PI(4,5)P2 and PI(3,4,5)P3 are thought to be acutely produced during endo- and exocytic cycles, this model also implies that Sky can be dynamically engaged during specific vesicle trafficking steps.
The behavioural deficits seen upon expression of the clinical mutants correlate with synaptic vesicle trafficking defects that we also observed in loss-of-function sky mutants20, indicating the clinical mutants also cause loss of a sky/TBC1D24 function. The defects in the pathogenic mutants are less severe than those seen in sky1/2 mutants, indicating they are partial loss of function alleles. This correlates with the observation that the pathogenic mutations in the phosphoinositide binding pocket significantly reduce the affinity for IP3 and PI(4,5)P2, while they do not completely abolish binding. Moreover, the in vivo phenotypes might also be alleviated to a certain extent because the mutants are over expressed, driving the mutant protein to bind membranes. It is conceivable that these defects in membrane targeting of the clinical Sky mutants will in turn affect the interactions with partner proteins at the correct membrane compartments, eventually leading to trafficking defects.
1. Cloning, Protein Expression and Protein Purification
For the structural and biochemical analyses the TBC domain of Sky (Sky1-353) was expressed from the pET28a vector (Novagen) as an N-terminal His6-tag fusion. All point mutations were created using QuickChange mutagenesis with Pfu high-fidelity DNA polymerase (Thermo Fisher Scientific). Wild-type and mutant proteins were expressed in E. coli C41 (DE3) cells and purified by immobilized metal ion affinity chromatography and size exclusion chromatography.
2. Structure Determination
Crystals of Sky1-353 were obtained by the sitting drop vapor diffusion method at 277 K. Crystals of native and SeMet-labeled proteins were obtained in the presence of 20% PEG 3350 and 0.2 M ammonium citrate tribasic pH 7.0. The complex of Sky1-353 with IP3 was obtained by soaking crystals grown in 25% PEG 1500 and 0.1 M succinate/phosphate/glycine pH 7.0 with 5 mM IP3 (Merck Millipore) for 1 h. Before flash freezing in liquid nitrogen all crystals were briefly soaked in mother liquor supplemented with 25% glycerol. Data were collected at 100 K at the Proxima 2 beamline of the SOLEIL synchrotron for native and SeMet-labeled protein, and at the 1D23-1 beamline of the ESRF synchrotron for Sky1-353 in complex with IP3. Diffraction data were integrated and scaled with the program XDS52. The SeMet-labelled Sky1-353 structure was solved using the single-wavelength anomalous diffraction (SAD) method at the SeMet peak wavelength using Autosol and Autobuild from the Phenix suite53. This initial low resolution model was then used to solve the structure of the high resolution native Sky1-353 structure using molecular replacement with Phaser54. The latter structure was used to solve the Sky1-353-IP3 complex with molecular replacement. Models were then improved by iterative cycles of refinement with Phenix and manual building in Coot55. MolProbity was used for structure validation56. X-ray data collection and refinement statistics are listed in Table 1.
3. Lipid Binding and Thermal Shift Assays
Liposomes were prepared using either Folch brain total lipid extract or using a mix of phosphatidylcholine and phosphatidylserine (80:20 ratio) supplemented with 0.5%, 2% or 5% of a specific phosphoinositide as indicated. The liposomes were subsequently incubated with 6 μg of wild-type or mutant Sky1-353. PI(4,5)P2-Grip (Echelon Biosciences, Salt Lake City, USA) was used as a positive control. Subsequently, this mix was loaded on a sucrose cushion (30% sucrose layer, 25% sucrose layer and HP30 buffer layer) and centrifuged. Individual fractions from the top to the bottom were collected and assayed using Western blotting against His6 (Sky) or GST (PI(4,5)P2-Grip).
Titration curves for binding of IP3 to Sky1-353 were obtained via thermal shift assays at different concentrations of IP3. Thermal unfolding was detected by following SYPRO orange fluorescence using a CFX connect Real-Time PCR System (BioRad). 0.2 mg/ml (4.7 μM) protein was combined with 3×SYPRO Orange Protein Gel Stain (Thermo Fisher Scientific) at different concentrations of MgSO4 and IP3. The temperature was increased from 20° C. to 80° C. at 0.5° C./30s steps. All measurements were done in triplicate. Plots of Tm versus IP3 or MgSO4 concentration were fitted on a quadratic equation.
4. Genetics
Fly stocks were reared on standard corn meal and molasses medium at 21° C. For experiments, mutants and controls were grown in optimal conditions on grape juice plates with fresh yeast paste. sky mutants are yw eyFLP; FRT40A sky1/FRT40A sky2 and wild type controls are yw eyFLP; FRT40A as previously described20. Synaptojanin mutants are eyFLP; FRT42D synj1 as previously described26 and the sky1 allele (on 2L) was recombined with the synj1 allele (on 2R). The presence of FRT40A or FRT42D was not verified. nSybGal4 is from the Bloomington Drosophila stock center. Wild type sky cDNA, patient mutation alleles and triple mutations in the positive pocket were based on BDGP cDNA clone LD10117 and were synthesized from three overlapping DNA blocks (Integrated DNA Technologies) with overlapping ends and a pUAST-attB vector backbone57. The second DNA block was adapted to include either a patient single mutation or triple point mutations. DNA blocks and the pUAST-attB vector were digested with NotI and XhoI restriction enzymes and ligated via Gibson Assembly58 (New England Biolabs, Ipswich, USA), and correct synthesis and ligation confirmed by sequencing. UAS-Sky and all Sky mutants were inserted into the genome using φC31-mediated integration at the VK33 (cytological location 65B2, PBac{yellow+-attP-3B}VK00033) docking site on the third chromosome. Primers for UAS-Sky cDNA amplification are: for: 5′agaattcATGCCATACCATCGAGGCGG3′; rev: 5′aagcggccgcTTAGATGCCCACGAATCCGTAG3′ (EcoRI and NotI restriction sites in lower case).
5. FRAP Assay
Sky1/2 larvae overexpressing the Sky cDNAs GFP-SkyWT, GFP-SkyR79C, GFP-SkyR281C, GFPSky3Glu driven by nSybGal4 were dissected in HL-3 (in mM: NaCl (110), KCl (5), NaHCO3 (10), HEPES (5), sucrose (30), trehalose (5), MgCl2 (10) pH 7.2), segmental nerves were cut and NMJ boutons of muscles 6/7 were imaged on a Nikon Al R confocal microscope and 60×1.0 NA water immersion lens at 1 fps. For photobleaching a region of 20% of the bouton surface was selected and stimulated in a single scan step at λ=405 nm (90.1%) and 488 nm (99.8%) for <1 s. The recovery of fluorescence in the bleached region was measured over the course of 1 min at room temperature using standard GFP optics. The time constant τ of the recovery curve was determined for each genotype. We also assessed the photo-recovery of Synaptotagmin-GFP (Syt), a protein that is always associated with vesicle membranes (Syt is a transmembrane protein).
6. FM 1-43 Dye Uptake
Third instar larvae were dissected in HL-3 and motor neurons were cut. Stimulation in the presence of FM 1-43 (4 μM) (Invitrogen), for 1 min was performed using HL-3 with 90 mM KCl: (mM) NaCl (25), KCl (90), NaHCO3 (10), HEPES (5), sucrose (30), trehalose (5), MgCl2 (10), CaCl2 (1.5), pH 7.2. Non-internalized dye was removed by washing with HL-3. FM 1-43 at two muscle 6/7 NMJ was recorded with a Nikon Al R confocal microscope and 60×1.0 NA water immersion lens at room temperature utilizing λ=488 nm excitation and a 510/20 nm band pass emission filter.
7. Transmission Electron Microscopy
Third instar larvae were dissected in HL-3 and motor neurons cut. Preparations were stimulated for 1 min in HL-3 with KCl (60 mM KCl and 1.5 mM CaCl2), followed by fixation (1% glutaraldehyde, 4% paraformaldehyde, 1 mM MgCl2 in 0.1 M Na-cacodylate buffer, pH 7.4). Subsequently, larvae were osmicated in OsO4/Na-cacodylate for 2 h and stained in 2% aqueous uranyl acetate for 1.5 h. Specimens were dehydrated in a graded ethanol series and embedded in Agar 100 (Laborimpex, Agar Scientific). Ultrathin sections (60-70 nm) were collected on butvar coated grids (Laborimpex, Agar Scientific). Grids were recorded with a JEM1400 (JEOL) transmission electron microscope at 80 kV. To analyze synaptic boutons, ultrastructural profile areas and synaptic vesicle content were quantified in ImageJ (NIH).
8. Animal Behaviour
Adult flies of the genotype sky1/sky2 (sky1/2); nsyb-Gal4/UAS-SkyR79C or genotypes as indicated, were raised at 21° C. on standard fly food, containing the indicated drugs (Miltefosine, Perifosine, Edelfosine, Erufosine) or on control food prepared without drugs. Animals were collected and gender selected 2 to 5 days after enclosure. On days 2 and 8 of incubation on drugs, flight assays were performed with groups of 5 gender-selected animals in each transparent vial. Following a tap to collect the animals at the bottom of the vial, behaviour was distinguished between walking, jumping and flight. Seizure assays were performed with groups of 10 gender-selected animals that were transferred into transparent vials and excited by vortexing once for 10 seconds in behaviour studies, or in a sequence (1 minute vortexing, 1 minute rest, 1 minute vortexing) for drug treatment studies. This test sequence was repeated following 5 minutes of rest. Active and fallen flies were quantified over the course of the following minute. To ensure natural behaviour animals were not anesthetized on the day of experiments or over the course of drug application.
9. Biochemical Screening Assay for Synj1 5′-Phosphatase Domain-Specific Inhibitors.
The Malachite Green Phosphate Assay Kit (BioAssay Systems) is a discontinuous assay that measures the concentrations of enzymatically released phosphate after formation of a complex with malachite green and molybdate (absorbance is measured at 620 nm). The assay optimized for screening of inhibitory compounds was used according to manufacturers protocol, with the 5′-phosphatase domain of Synj1 (200 nM HIS-tagged human SYNJ1 amino acid 528-873 (hSYNJ1 corresponds to SEQ ID NO:1)) as enzyme, and inositol-3-phosphate (40 μM IP3) (Merck Millipore) as substrate, in buffer 25 mM HEPES pH 7.5, 150 mM NaCl, 5% glycerol, and 1 mM DTT. As a read-out the Absorbance at 620 nm after 60 min incubation is measured and the background starting signal is subtracted. For inhibitory compound screening, 1 mM of the test compound dissolved in 1% DMSO was used.
| Number | Date | Country | Kind |
|---|---|---|---|
| 1614609.4 | Aug 2016 | GB | national |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/EP2017/071622 | 8/29/2017 | WO | 00 |
